DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Roche - 4 — - 2 Teresa Graham - 2 Roivant - 1 Vivek Ramaswamy's - 1 Pfizer - 1 TL1a - 1 that's - 1
Top related locs:
Japan Roivant Swiss U.S Chevron China
Top related orgs:
Pfizer - 4 Telavant Holdings - 4 Roivant Sciences - 3 pharma - 2 Wall Street Journal - 1 Service - 1 Food and Drug Administration - 1 Roivant - 1

Search resuls for: "Telavant Holdings"


4 mentions found


☆ A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free
  + stars: | 2023-10-24 | by ( Filip De Mott | ) www.businessinsider.com   time to read: +4 min
Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. AdvertisementAdvertisementRoche's acquisition of a bowel-inflammation treatment delivered a massive windfall for presidential candidate Vivek Ramaswamy's company Roivant, the Wall Street Journal reported. But Roivant's expenses to develop the treatment, which targets an inflammatory protein called TL1A, amounted to just $15 million. And just this month, a $1.5 billion collaboration between Sanofi and Teva Pharmaceuticals was announced for more TL1A treatment. "This is a $15 billion market just in the US, and that's just in [inflammatory bowel disease," Roche chief Teresa Graham told the Journal.
Persons: Roche, Roivant, —, Vivek Ramaswamy's, Pfizer, TL1a, that's, " Roche, Teresa Graham Organizations: Wall Street Journal, Pfizer, Service, Telavant Holdings, Food and Drug Administration, Roivant, Prometheus Biosciences, Merck, Sanofi, Teva Pharmaceuticals, pharma Locations: Roivant, Japan
☆ Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion
  + stars: | 2023-10-23 | by ( Adrià Calatayud | ) www.wsj.com   time to read: 1 min
Roche’s deal is the latest example of a big pharma company turning to the deal table to bolster its pipeline of autoimmune drugs. Photo: Philipp Schmidli/Bloomberg NewsRoche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences , a company started by Republican presidential candidate Vivek Ramaswamy , and Pfizer in a deal worth more than $7 billion. The Swiss pharmaceutical giant said Monday it would pay $7.1 billion upfront for Telavant Holdings, and make a near-term milestone payment of $150 million. Roche said the deal gives it rights to commercialize Telavant’s RVT-3101 drug candidate, which has shown promise for inflammatory-bowel disease and could have potential in other indications, in the U.S. and Japan.
Persons: Philipp Schmidli, Vivek Ramaswamy, Roche Organizations: pharma, Bloomberg, Roche Holding, Roivant Sciences, Republican, Pfizer, Telavant Holdings, Telavant’s Locations: Swiss, U.S, Japan
☆ Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings
  + stars: | 2023-10-23 | by ( Hannah Ward-Glenton | ) www.cnbc.com   time to read: +1 min
Swiss health care company Roche on Monday announced it would acquire Telavant Holdings in a $7.1 billion transaction. Telavant produces drugs for people suffering from inflammatory and fibrotic diseases and is in the process of developing a "promising new therapy" for patients with Crohn's disease, Roche said in a press release. "We are eager to develop this antibody further and bring it to market and patients in the US and Japan as soon as possible." Telavant is currently owned by Pfizer and Roivant Sciences. In the Monday announcement, Roche also said it would obtain an option to collaborate with Pfizer on a new inflammatory bowel disease drug.
Persons: Roche, — Roche, Teresa Graham, Telavant Organizations: Monday, Telavant Holdings, Roche Pharmaceuticals, CNBC, Pfizer, Roivant Sciences Locations: Japan
☆ Stocks making the biggest moves premarket: Chevron, Apple, Walgreens Boots Alliance and more
  + stars: | 2023-10-23 | by ( Samantha Subin | ) www.cnbc.com   time to read: +2 min
Chevron , Hess — Chevron shares slumped more than 2% after the oil giant said its buying smaller rival Hess in an all-stock deal totaling $53 billion, or $171 a share. Hess shares moved slightly higher. Walgreens Boots Alliance — The pharmacy operator rose nearly 3% after JPMorgan upgraded Walgreens Boots Alliance shares to overweight from neutral. Salesforce — The software giant lost nearly 2% after Piper Sandler downgraded shares to neutral from overweight, citing heightened execution and M & A risks. Bank of America downgraded Alcoa to a neutral rating and slashed its price target, citing concerns of a near-term earnings decline.
Persons: Hess, Stonepeak, Piper Sandler, Roche, —, Jesse Pound Organizations: Hess, Chevron, Apple, Global Times, Walgreens, Alliance, JPMorgan, Roivant Sciences, Pfizer, Telavant Holdings, Citi, Evercore, Alcoa, Bank of America Locations: Chevron, China
0 next >>
Total: 4